Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitonin.
A patient with a pancreatic islet cell tumor concurrently producing vasoactive intestinal polypeptide (VIP) and calcitonin with related symptoms is presented. The patient was given palliative treatment consisting of octreotide, streptozotocin and 5-fluorouracil, and survival now exceeds 72 months. The concurrent production of VIP and calcitonin by a pancreatic islet cell tumor has not been described before.
Eskens
F A
FA
Department of Medicine, University Hospital Nijmegen, The Netherlands.
Roelofs
E J
EJ
Hermus
A R
AR
Verhagen
C A
CA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001706:Biopsy; D002116:Calcitonin / Q000032:analysis / Q000096:biosynthesis* / Q000097:blood; D018572:Disease-Free Survival; D004701:Endocrine Gland Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007150:Immunohistochemistry; D007515:Islets of Langerhans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015282:Octreotide / Q000008:administration & dosage; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology / Q000532:radiotherapy; D013311:Streptozocin / Q000008:administration & dosage; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D014660:Vasoactive Intestinal Peptide / Q000032:analysis / Q000096:biosynthesis* / Q000097:blood
D014660:Vasoactive Intestinal Peptide; D013311:Streptozocin; D002116:Calcitonin; D015282:Octreotide; D005472:Fluorouracil